Click Here for 5% Off Your First Aladdin Purchase!

Tandutinib (MLN518) - ≥98%, high purity , Platelet-derived growth factor receptor beta inhibitor, CAS No.387867-13-2, Platelet-derived growth factor receptor beta inhibitor

  • Moligand™
  • ≥98%
Item Number
T125150
Grouped product items
SKUSizeAvailabilityPrice Qty
T125150-25mg
25mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$31.90
T125150-100mg
100mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$103.90
T125150-500mg
500mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$468.90

Basic Description

SynonymsTandutinib|387867-13-2|MLN-518|CT53518|MLN518|Tandutinib (MLN518)|MLN 518|CT 53518|CT-53518|N-(4-isopropoxyphenyl)-4-(6-methoxy-7-(3-(piperidin-1-yl)propoxy)quinazolin-4-yl)piperazine-1-carboxamide|4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsTandutinib is a piperazinyl quinazoline receptor tyrosine kinase inhibitor with antineoplastic activity. Tandutinib inhibits the autophosphorylation of Flt-3/Flk-2 (FMS-Like Tyrosine kinase-3), c-KIT and PDGF (platelet-derived growth factor) receptor tyro
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionPlatelet-derived growth factor receptor beta inhibitor
Note卖完停产,不再备货
Product Description

Tandutinib (MLN518, CT53518) is a potent FLT3 antagonist with IC50 of 0.22 μM, also inhibits PDGFR and c-Kit, 15 to 20-fold higher potency for FLT3 versus CSF-1R and >100-fold selectivity for the same target versus FGFR, EGFR and KDR.
A piperazinyl quinazoline receptor tyrosine kinase inhibitor

Product Properties

ALogP4.6

Names and Identifiers

IUPAC Name 4-[6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl]-N-(4-propan-2-yloxyphenyl)piperazine-1-carboxamide
INCHI InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)
InChi Key UXXQOJXBIDBUAC-UHFFFAOYSA-N
Canonical SMILES CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCCC5
Isomeric SMILES CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCCC5
PubChem CID 3038522
Molecular Weight 562.72

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

1 results found

Lot NumberCertificate TypeDateItem
G1706080Certificate of AnalysisFeb 06, 2023 T125150

Chemical and Physical Properties

SolubilitySoluble in water (very poorly), DMSO (25 mg/ml, with slight warming), ethanol (25 mg/ml, with slight warming), and chloroform.
Melt Point(°C)172-183°C

Related Documents

References

1. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N et al..  (2002)  CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)..  Cancer Cell,  (5): (421-32).  [PMID:12124172]

Solution Calculators